KORTUC hits 184-patient enrolment in registrational breast cancer trial
KORTUC has completed enrolment of 184 patients in its registrational, randomised Phase 2 breast cancer trial, marking the primary recruitment milestone for the Palo Alto-based company's lead programme. The study, led by The Institute of Cancer Research in the United Kingdom, is now entering its follow-up and data analysis phase, with an efficacy readout targeted for 2027.
The trial compares radiotherapy alone against radiotherapy plus KRC-01, the company's proprietary intratumoral radiosensitizer, in patients with primary or recurrent locally advanced breast cancer. The primary endpoint is complete response, defined as no detectable tumour on MRI after treatment. Ten clinical sites are involved, split across six UK centres and four in India.
How KRC-01 works
KRC-01 is an intratumoral formulation of hydrogen peroxide and sodium hyaluronate. The rationale centres on tumour hypoxia, a condition in which solid tumours maintain low oxygen levels that can blunt the effect of radiotherapy. The company says KRC-01 is designed to raise intratumoural oxygen and inactivate antioxidative enzymes associated with radioresistance. Sodium hyaluronate is included to slow the decomposition of hydrogen peroxide, helping the active agent persist within the tumour during radiation delivery. KORTUC cites figures suggesting hypoxia affects more than half of solid tumours, though this estimate is drawn from company materials and has not been independently verified here.
Chief executive Kazu Matsuda said the enrolment milestone "moves our lead program beyond target recruitment and toward data readout," adding that the cervical and rectal programmes extend the evaluation of KRC-01 into cancers where hypoxia similarly constrains radiation response.
Three-programme pipeline
Beyond the breast cancer study, KORTUC is running two further trials. A global Phase 1/2 cervical cancer study, conducted in partnership with the University of California San Diego, is enrolling 70 patients with untreated, locally advanced disease. First enrolment began in March 2026. The study is structured as a ten-patient safety and dose-schedule phase followed by a 60-patient randomised comparison of standard chemoradiotherapy with or without KRC-01; progression-free survival is the primary endpoint for the randomised portion. Sites are registered in Thailand, India and the UK.
A third programme, the Phase 2 K-BOOST rectal cancer study, has received authorisation to proceed in France and is sponsored by Gustave Roussy. That trial will enrol 24 adults with non-metastatic, high-risk stage III rectal cancer at Gustave Roussy and Institut Bergonié. The primary endpoint is clinical complete response at week 24, and the investigators will explore whether KRC-01 can support an organ-preservation pathway, avoiding surgery for eligible patients.
Market and competitive context
The radiosensitizer space is a niche but growing corner of radiation oncology. Interest in overcoming hypoxia-driven radioresistance has a long academic history, and several investigational agents have been evaluated over the decades with limited clinical traction. KRC-01's approach, using an off-patent chemical combination in a novel formulation, is positioned as relatively low-cost compared with biologics or advanced cell therapies. That could be a commercial differentiator if efficacy data support it, particularly in healthcare systems where treatment affordability shapes adoption decisions.
The 2027 breast cancer readout will be the first registrational dataset for KRC-01 and will determine whether the company has a viable path to regulatory submission. Complete response as a primary endpoint in locally advanced breast cancer is well-recognised by regulators, though the FDA and EMA have increasingly scrutinised whether complete response data alone are sufficient to support accelerated approval without overall survival follow-up. KORTUC will need to navigate that landscape carefully as it prepares its regulatory strategy.